CLDN2 and breast cancer: Given the role of this SFK-c-Fos pathway in regulating Claudin-2 expression, we predicted that pan-SFK inhibitors would, in fact, enhance breast cancer metastasis to the liver, through the transcriptional up-regulation of Claudin-2.